One year after establishing the strategic development group for innovation in the medical field, particularly in pharmaceuticals, the strategic framework for advancing clinical trials in Romania has been finalized. On June 27, 2024, the Ministry of Health, the National Agency of Medicines and Medical Devices from Romania, the G6-UMF University Alliance, and the Local American Working Group Association hosted the launch event for the "STRATEGIC PLAN FOR THE DEVELOPMENT OF CLINICAL STUDIES IN THE FIELD OF MEDICINES FOR HUMAN USE IN ROMANIA" at "Carol Davila" UMF.
This strategic plan is a milestone for Romania, being the country's first comprehensive blueprint dedicated to clinical studies. Developed within the Health Innovation Hub and under the strategic coordination of the Romanian National Medicines and Medical Devices Agency, the plan involved extensive collaboration among all key stakeholders in the field. Participants included health authorities, the medical academic community, clinical investigators, patient representative associations, the innovative pharmaceutical industry, the Romanian clinical trial coordinating industry, and experts in public health and economic policies. Additionally, the plan benefited from the technical expertise of IQVIA Romania, ensuring a robust and effective framework.
The launch event at UMF "Carol Davila" brought together a diverse group of stakeholders, reflecting a united effort to propel Romania to the forefront of clinical research and pharmaceutical development. The strategic plan aims to enhance the quality, efficiency, and scope of clinical trials in Romania, providing a clear and structured path forward. It emphasizes the importance of collaboration among various entities, including health authorities, academia, industry experts, and patient groups, to achieve a common goal of medical innovation and improved healthcare outcomes.
The Avantyo Institute of Clinical Research, which has actively supported the development of clinical trials in Romania over the years by organizing the Annual Clinical Trials Symposium, round tables, and webinars alongside competent authorities, academia, patient associations, CRO's, and the pharmaceutical industry, participated in this event of great importance.
In summary, the strategic plan marks a transformative step for Romania's clinical trials sector. It showcases a collective vision and a concerted effort to advance medical research, benefiting patients and the broader medical community. The involvement of diverse stakeholders ensures a comprehensive approach to the development and execution of clinical trials, promising significant advancements in the field. The launch of this strategic plan not only sets a precedent for future initiatives but also positions Romania as a key player in global medical research and innovation.
